| For: | Shan GY, Wan H, Zhang YX, Cheng JY, Qiao DR, Liu YY, Shi WN, Li HJ. Pathogenesis and research progress of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Hepatol 2024; 16(10): 1142-1150 [PMID: 39474575 DOI: 10.4254/wjh.v16.i10.1142] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v16/i10/1142.htm |
| Number | Citing Articles |
| 1 |
Xueying Wang, Zhiying Wei, Qing Xiang, Lijie Tang, Weichun Xie. Therapeutic Potential of Probiotics in Metabolic Dysfunction-Associated Steatohepatitis: A Comprehensive Review. Microorganisms 2025; 13(8) doi: 10.3390/microorganisms13081894
|
| 2 |
Muhammad Asim, Aleena Altaf, Aamir Sohail, Maimoona Arshad, Faiza Noreen, Idrees Raza, Hamza Muneer, Muhammad Murtaza Hasnain, Raza Sufyan, Imran Ullah. Steatosis - Causes and Treatment. 2025; doi: 10.5772/intechopen.1011551
|
| 3 |
Cherdsak Boonyong, Sasiwimon Nukulkit, Darunee Sertphon, Pairin Ponpaipal, Napat Prompat, Nonthalert Lertnitikul. Network pharmacology, molecular docking, and molecular dynamics simulation study of phytoconstituents from Baliospermum solanifolium roots for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Phytomedicine Plus 2026; 6(4) doi: 10.1016/j.phyplu.2026.101043
|
| 4 |
Soo Yeon Kim, Siwoo Lee, Hee-Jeong Jin. Transcription factor EB activation by platycodin D: A novel therapeutic strategy for hepatic steatosis through enhanced lipophagy. Genes & Diseases 2027; 14(2) doi: 10.1016/j.gendis.2026.102149
|
| 5 |
Xinyang Huang, Zihao Deng, Xiaozhou Li, Songxin Yan, Kunjiang Zhong, Fengning Yuan, Ligang Liu, Chaolin Deng, Tingting Liu, Ruizhao Zhao, Amin Buhe, Tianxiong Li, Hao Zhao. Serum LEAP2 Levels Across the Spectrum of Metabolic Dysfunction-Associated Fatty Liver Disease: A Potential Noninvasive Biomarker for Severity Stratification. Diabetes, Metabolic Syndrome and Obesity 2025; doi: 10.2147/DMSO.S536270
|
| 6 |
Yuliang Liu, Xiang Meng, Wei Zhang, Mengmeng Sun, Ziyoviddin Yusupov, Komiljon Tojibaev, Kobil A. Bobokalonov, Zhenghai Zhang, Min He, Meiying Jin. The zebrafish model: a versatile platform for uncovering the therapeutic potential of phytochemicals in liver diseases. Frontiers in Pharmacology 2026; 17 doi: 10.3389/fphar.2026.1794777
|
| 7 |
D. V. Emelyanov. Особливості стоматологічного статусу хворих при різних патогенетичних формах неалкогольної жирової хвороби печінки. Likarska sprava 2025; (1) doi: 10.31640/LS-2025-1-04
|
| 8 |
Abdallah Hussein, Ameer Awashra, Islam Rajab, Mohammad Bdair, Dawoud Hamdan, Ahmad Nouri, Elaf Khatib, Ghiras Khatib, Nyan Latt. Comparative Effectiveness of Bariatric Surgery Versus GLP‐1 Receptor Agonists in Reducing the Risk of New‐Onset of NASH: A Retrospective Multinational Cohort Study From North America and Europe. Endocrinology, Diabetes & Metabolism 2025; 8(4) doi: 10.1002/edm2.70075
|
| 9 |
Chunmei Ran, Xiaoyan Gao, Yongqin Zhou, Chibing Dai. Critical role of interleukin-33 in pathogenesis and progression of metabolic dysfunction-associated steatotic liver disease. Frontiers in Medicine 2026; 13 doi: 10.3389/fmed.2026.1762478
|